CN112166126A - 半乳糖凝集素-10抗体 - Google Patents

半乳糖凝集素-10抗体 Download PDF

Info

Publication number
CN112166126A
CN112166126A CN201980035738.2A CN201980035738A CN112166126A CN 112166126 A CN112166126 A CN 112166126A CN 201980035738 A CN201980035738 A CN 201980035738A CN 112166126 A CN112166126 A CN 112166126A
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
galectin
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980035738.2A
Other languages
English (en)
Chinese (zh)
Inventor
B·兰布雷希特
S·萨维德斯
H·哈马德
K·凡斯崔特
J-M·佩西耶
C·布朗什托
M·桑德斯
H·德哈德
B·范德旺宁
E·佩尔松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universiteit Gent
Vlaams Instituut voor Biotechnologie VIB
ArgenX BVBA
Original Assignee
Flemish Biotechnology Institute
Universiteit Gent
ArgenX BVBA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1806099.6A external-priority patent/GB201806099D0/en
Priority claimed from GBGB1901648.4A external-priority patent/GB201901648D0/en
Application filed by Flemish Biotechnology Institute, Universiteit Gent, ArgenX BVBA filed Critical Flemish Biotechnology Institute
Publication of CN112166126A publication Critical patent/CN112166126A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4724—Lectins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201980035738.2A 2018-04-13 2019-04-12 半乳糖凝集素-10抗体 Pending CN112166126A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1806099.6A GB201806099D0 (en) 2018-04-13 2018-04-13 Galectin-10 Antibodies
GB1806099.6 2018-04-13
GBGB1901648.4A GB201901648D0 (en) 2019-02-06 2019-02-06 Galectin-10 antibodies
GB1901648.4 2019-02-06
PCT/EP2019/059570 WO2019197675A1 (en) 2018-04-13 2019-04-12 Galectin-10 antibodies

Publications (1)

Publication Number Publication Date
CN112166126A true CN112166126A (zh) 2021-01-01

Family

ID=66240109

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980035738.2A Pending CN112166126A (zh) 2018-04-13 2019-04-12 半乳糖凝集素-10抗体

Country Status (12)

Country Link
US (3) US11066473B2 (https=)
EP (1) EP3774905A1 (https=)
JP (1) JP2021520825A (https=)
KR (1) KR20210005070A (https=)
CN (1) CN112166126A (https=)
AU (1) AU2019250689A1 (https=)
BR (1) BR112020020868A2 (https=)
CA (1) CA3094215A1 (https=)
IL (1) IL278010A (https=)
MX (1) MX2020010821A (https=)
SG (1) SG11202009140SA (https=)
WO (1) WO2019197675A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113666999A (zh) * 2021-08-31 2021-11-19 中国医学科学院基础医学研究所 用于治疗2型免疫疾病的多肽
CN113667000A (zh) * 2021-08-31 2021-11-19 中国医学科学院基础医学研究所 多肽在制备治疗2型免疫疾病的药物中的应用
CN113999287A (zh) * 2021-12-02 2022-02-01 深圳湾实验室坪山生物医药研发转化中心 一种靶向半乳糖凝集素-10的多肽抑制剂及其制备方法和用途
CN115785245A (zh) * 2022-07-18 2023-03-14 上海博满生物科技有限公司 一种半乳糖凝集素10晶体及其制备的抗体IgY和药物制剂
CN115902204A (zh) * 2022-09-23 2023-04-04 北京大学第三医院（北京大学第三临床医学院） 一种外泌体形式半乳糖凝集素9的检测方法与试剂盒

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020010821A (es) 2018-04-13 2021-01-15 Argenx Iip Bv Anticuerpos contra galectina-10.
US11860114B2 (en) * 2020-03-26 2024-01-02 David Hurwitz Determining atomic coordinates from X-ray diffraction data
WO2021223079A1 (zh) * 2020-05-06 2021-11-11 科稷达隆(北京)生物技术有限公司 一种纳米抗体及其应用
IL314367A (en) 2022-01-18 2024-09-01 argenx BV Antibodies to galectin 10
KR20240133723A (ko) 2022-01-18 2024-09-04 아르제넥스 비브이 Fab 단편의 분무화
WO2023150260A2 (en) * 2022-02-03 2023-08-10 Regents Of The University Of Minnesota Compounds that target tem8, compositions, and methods
JPWO2023153496A1 (https=) * 2022-02-10 2023-08-17
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106645752A (zh) * 2016-12-27 2017-05-10 中南大学湘雅医院 Galectin‑10及其特异性抗体在制备检测鼻咽癌试剂盒中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
DE10333406A1 (de) * 2003-07-15 2005-02-10 Protagen Ag T-regulatorische-Zellen enthaltend Galectine zur Therapie und Diagnose von Erkrankungen
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
CA2988388C (en) * 2015-04-23 2022-11-22 Nantomics, Llc Cancer neoepitopes
MX2020010821A (es) 2018-04-13 2021-01-15 Argenx Iip Bv Anticuerpos contra galectina-10.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106645752A (zh) * 2016-12-27 2017-05-10 中南大学湘雅医院 Galectin‑10及其特异性抗体在制备检测鼻咽癌试剂盒中的应用

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113666999A (zh) * 2021-08-31 2021-11-19 中国医学科学院基础医学研究所 用于治疗2型免疫疾病的多肽
CN113667000A (zh) * 2021-08-31 2021-11-19 中国医学科学院基础医学研究所 多肽在制备治疗2型免疫疾病的药物中的应用
CN113666999B (zh) * 2021-08-31 2022-08-19 中国医学科学院基础医学研究所 用于治疗2型免疫疾病的多肽
CN113999287A (zh) * 2021-12-02 2022-02-01 深圳湾实验室坪山生物医药研发转化中心 一种靶向半乳糖凝集素-10的多肽抑制剂及其制备方法和用途
CN115785245A (zh) * 2022-07-18 2023-03-14 上海博满生物科技有限公司 一种半乳糖凝集素10晶体及其制备的抗体IgY和药物制剂
WO2024016762A1 (zh) * 2022-07-18 2024-01-25 上海博满生物科技有限公司 一种半乳糖凝集素10晶体及其制备的抗体IgY和药物制剂
CN115902204A (zh) * 2022-09-23 2023-04-04 北京大学第三医院（北京大学第三临床医学院） 一种外泌体形式半乳糖凝集素9的检测方法与试剂盒

Also Published As

Publication number Publication date
SG11202009140SA (en) 2020-10-29
EP3774905A1 (en) 2021-02-17
JP2021520825A (ja) 2021-08-26
WO2019197675A1 (en) 2019-10-17
CA3094215A1 (en) 2019-10-17
MX2020010821A (es) 2021-01-15
US11713354B2 (en) 2023-08-01
US20240026010A1 (en) 2024-01-25
US11066473B2 (en) 2021-07-20
KR20210005070A (ko) 2021-01-13
US20190367619A1 (en) 2019-12-05
BR112020020868A2 (pt) 2021-04-06
US20210332140A1 (en) 2021-10-28
AU2019250689A1 (en) 2020-10-08
IL278010A (en) 2020-11-30

Similar Documents

Publication Publication Date Title
US11713354B2 (en) Galectin-10 antibodies
US11242404B2 (en) Antibodies against signal-regulatory protein alpha and methods of use
JP6345800B2 (ja) 抗体−フィノマー複合体
RU2742606C2 (ru) Антитела к с5 и способы их применения
AU2018382527B2 (en) Anti-alpha synuclein antibodies
JP2025087672A (ja) 抗ｋｌｋ７抗体、抗ｋｌｋ５抗体、多重特異性抗ｋｌｋ５／ｋｌｋ７抗体および使用方法
US20230088269A1 (en) Anti-il-22r antibodies
KR20170081253A (ko) 항-il-1베타 항체 및 이의 사용 방법
CN115925935A (zh) 抗人gpvi抗体及其用途
JP2024518724A (ja) 抗ｍａｓｐ２抗体、その抗原結合断片および医薬用途
JP7080352B2 (ja) 糖タンパク質ｖｉを標的とする抗体
TW202509068A (zh) 結合ox40l之抗體及使用方法
TW202444762A (zh) 自體免疫性疾病的治療
TW202229337A (zh) 犬抗體變異體
KR20250023381A (ko) C-kit 및/또는 시글렉을 표적화하는 항체 및 이의 용도
CA3235627A1 (en) Anti-activin a antibodies, compositions and uses thereof
KR20260051068A (ko) Enpp3 및 cd3 결합제 및 이의 사용 방법
HK40034251A (en) Galectin-10 antibodies
CN118488967A (zh) 半乳凝素-10抗体
EA047651B1 (ru) Антитела против галектина-10
JP2017057201A (ja) 抗体−フィノマー複合体を含む医薬組成物
BR122024025202A2 (pt) Anticorpos multiespecíficos, polinucleotídeo isolado, vetor de expressão, célula hospedeira, método para produzir anticorpos multiespecíficos, composição farmacêutica e uso
EA041304B1 (ru) СПОСОБ ПОЛУЧЕНИЯ АНТИ-C5 АНТИТЕЛА С БОЛЕЕ ВЫСОКОЙ АФФИННОСТЬЮ ПРИ pH 7,4, ЧЕМ ПРИ pH 5,8 (ВАРИАНТЫ)

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40034251

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20210520

Address after: Ghent

Applicant after: Argus IIP

Applicant after: VIB VZW

Applicant after: UNIVERSITEIT GENT

Address before: Zinvenarad, Belgium

Applicant before: Argenx Bvba

Applicant before: VIB VZW

Applicant before: UNIVERSITEIT GENT

CB02 Change of applicant information

Address after: Ghent

Applicant after: Agnes Benelux Co.

Applicant after: VIB VZW

Applicant after: UNIVERSITEIT GENT

Address before: Ghent

Applicant before: Argus IIP

Applicant before: VIB VZW

Applicant before: UNIVERSITEIT GENT

CB02 Change of applicant information
TA01 Transfer of patent application right

Effective date of registration: 20230619

Address after: Tianjin Weinalade Belgium

Applicant after: Argenx Bvba

Applicant after: VIB VZW

Applicant after: UNIVERSITEIT GENT

Address before: Ghent

Applicant before: Agnes Benelux Co.

Applicant before: VIB VZW

Applicant before: UNIVERSITEIT GENT

TA01 Transfer of patent application right
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210101